Charles River Laboratories Inte (CRL) Stock Price & How to Invest

Charles River Laboratories International, Inc. is a leading global contract research organization that helps pharmaceutical and biotech companies discover, develop, and safely test new drugs. It runs three reporting segments: Research Models and Services (RMS), which breeds and supplies purpose-bred lab animals and related services; Discovery and Safety Assessment (DSA), its largest segment, which runs toxicology and safety-testing studies that drugs must pass before human trials; and Manufacturing Solutions, which provides quality-control testing for biologics, cell and gene therapies, and other products. Charles River says it has supported a large majority of the drugs approved by the FDA in recent years, which underlines how embedded it is in the industry's R&D pipeline.

The investment picture in 2026 centers on a demand cycle and corporate change. After a stretch of soft biopharma funding that pressured DSA bookings, the company pointed to improving net bookings and cautious optimism that positive demand trends would continue into 2026. Quarterly revenue has been roughly flat to slightly up year over year, and management is running a cost-savings program targeting substantial annual savings. The bigger catalyst is activism: Elliott Investment Management took a large stake, reached a cooperation agreement in 2025 that added directors, and pushed a comprehensive strategic review, including a review of the Manufacturing Solutions segment and potential portfolio changes. That makes CRL both an operating story (does biopharma R&D spending recover?) and a special-situations story (what does the strategic review unlock?).

The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. Client concentration and the lumpiness of large study bookings add volatility to any given quarter. The activist strategic review is a double-edged sword: it could unlock value, but the outcome, timing, and any divestitures are uncertain and may disappoint. Regulatory and reputational scrutiny around animal research, plus a long-term industry shift toward non-animal testing methods, could pressure the RMS segment over time. The company also carries debt from past acquisitions, so a prolonged demand slump would weigh on cash flow and flexibility. Competition from other large CROs on price and capacity is persistent.

14 analysts publish price targets on CRL, averaging $228.50 against a $232.51 price as of August 2026, or -1.7%. The published targets run from $135.00 to $264.00, a moderate spread, and the ratings split 12 buy, 3 hold, 1 sell. Over the last six months there have been 7 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CRL forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Charles River Laboratories Inte. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Biopharma R&D demand recovery. Charles River's revenue tracks how much pharma and biotech companies spend on early-stage research, especially in its DSA safety-testing segment. The most optimistic published target, $264.00, assumes this works close to its best case.

The case against. The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. The most pessimistic target, $135.00, is roughly what CRL is worth if this bites instead.

Read the full bull and bear case on CRL, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Charles River Laboratories Inte's investor relations page or your broker.

• Revenue trend: Roughly flat to slightly up recently, with quarterly revenue around the $1 billion mark; annual revenue in the multi-billion range. Figures are approximate, verify live.
• Profitability: Profitable on an adjusted basis; GAAP earnings have been pressured by soft DSA demand and restructuring, with a cost-savings program aimed at protecting margins.
• Balance sheet: Carries acquisition-related debt; management has prioritized deleveraging and disciplined capital allocation. Confirm current leverage on the latest filing.
• Market cap tier: Mid-cap. Approximate figure has been in the several-billion-dollar range, well below its historical peak. Verify the live number.
• Valuation note: As a services business, CRL is typically valued on earnings and cash-flow multiples rather than a commodity price; multiples compressed during the demand downturn.
• Analyst coverage: Broadly covered by sell-side analysts, with views split between the demand-recovery bulls and cyclical-caution bears. Check current ratings and targets live.

All figures here are approximate and tied to the asOf date; verify live numbers on a current quote page or the latest SEC filing before acting. CRL is a services company, so its value depends on biopharma R&D demand, execution on cost savings, and the outcome of the strategic review, not on any single commodity price. Valuation multiples are more meaningful here than for a cyclical producer, but they still swing with where the demand cycle sits.

Other names that sit close to CRL: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CRL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CRL sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CRL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Charles River is the leading preclinical CRO, a critical supplier to biopharma R&D, now navigating a soft-demand cycle, an Elliott-driven strategic review, and a cost-savings push. It rewards a rebound in drug-development spending and value-unlocking moves, but earnings hinge on funding trends outside its control.

Whether CRL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRL a buy or a sell?, and where the stock could go from here in the CRL stock forecast.

For income investors, whether CRL pays a dividend and how the payout looks is covered in does CRL pay a dividend? And to weigh CRL against a peer, read the full side-by-side comparisons: CRL vs ICLR and CRL vs IQV.